The Myeloproliferative Disorders (MPD) Research Consortium focuses on the Philadelphia (Ph) chromosome negative MPD including Polycythemia Vera (PV), and Idiopathic Myelofibrosis (IM) and has the following goals: 1) Establish a multi-institutional international research group entitled the """"""""MPD Research Consortium"""""""" which will coordinate and facilitate basic and clinical research dealing with the cellular and genetic basis of the Ph negative MPD. 2) Establish a multi-institutional MPD Clinical Consortium to enable uniform, high volume sample collection, storage and distribution. 3) Perform rationally designed clinical trials in patients with Ph negative MPD at multiple institutions. 4) Maintain an interactive website for MPD Consortium investigators, a sophisticated international tissue bank and an on-line database that will allow for integration of basic and clinical research. This unique interactive relationship between talented basic researchers and clinical scientists will permit the MPD Research Consortium to develop novel clinical treatment programs for Ph negative MPD and to identify specific biomarkers that will be useful as indicators of therapeutic response and/or risk reduction. This program has six major projects: Project 1: Genetic Basis of Polycythemia Vera, Principal Investigator: Josef T. Prchal; Project 2: Mechanisms and Effects of NF-E2 and PRV-1 Overexpression in PV: Role of Jak2V617F, Principal Investigator: Heike L Pahl; Project 3: Animal Models of Polycythemia Vera, Principal Investigator: Jerry Spivak; Project 4: Mouse Models of Myelofibrosis, Principal Investigator: Anna Rita Migliaccio; Project 5: Abnormal Stem Cell Trafficking in Myelofibrosis, Principal Investigator: Ronald Hoffman; Project 6: MPD Clinical Consortium which will pursue clinical trials in PV and IM, Principal Investigator: Lewis Silverman and Co-Principal Investigator: Tiziano Barbui. The six projects will be supported by one core: Tissue Bank, Principal Investigator: Rona Weinberg. These unique interactions between clinical and laboratory investigators which are interwoven within the MPD Research Consortium will ultimately result in improved understanding of the pathobiology of the Ph negative MPD as well improved strategies that will assist in the diagnosis and treatment of these disorders. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108671-03
Application #
7251435
Study Section
Subcommittee G - Education (NCI)
Program Officer
Merritt, William D
Project Start
2006-07-01
Project End
2010-06-30
Budget Start
2008-09-22
Budget End
2009-06-30
Support Year
3
Fiscal Year
2008
Total Cost
$4,612,519
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Peeken, Jan C; Jutzi, Jonas S; Wehrle, Julius et al. (2018) Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood 131:2065-2073
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587
Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179

Showing the most recent 10 out of 195 publications